Aprea AB raises $51 mln
Aprea AB said Wednesday it raised 46 million euros ($51 million) in a series B round of financing led by Versant Ventures and 5AM Ventures. Sectoral Asset Management also participated in the round while HealthCap was local lead investor. Aprea's main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB and Rosetta Capital Ltd. Stockholm-based Aprea B is a clinical-stage biotechnology company developing anticancer compounds that aim to reactivate the tumor suppressor protein p53.
9 March 2016•4 mins read
